These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 26134366)

  • 1. Sensitization of HER2 Positive Breast Cancer Cells to Lapatinib Using Plants-Derived Isothiocyanates.
    Kaczyńska A; Świerczyńska J; Herman-Antosiewicz A
    Nutr Cancer; 2015; 67(6):976-86. PubMed ID: 26134366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of lapatinib with isothiocyanates overcomes drug resistance and inhibits migration of HER2 positive breast cancer cells.
    Kaczyńska A; Herman-Antosiewicz A
    Breast Cancer; 2017 Mar; 24(2):271-280. PubMed ID: 27154770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells.
    Vazquez-Martin A; Oliveras-Ferraros C; Colomer R; Brunet J; Menendez JA
    Ann Oncol; 2008 Jun; 19(6):1097-109. PubMed ID: 18283037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemical probing of HER2-amplified cancer cells identifies TORC2 as a particularly effective secondary target for combination with lapatinib.
    Amin DN; Ruiz-Saenz A; Gulizia N; Moasser MM
    Oncotarget; 2015 Dec; 6(38):41123-33. PubMed ID: 26516700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.
    Xia W; Petricoin EF; Zhao S; Liu L; Osada T; Cheng Q; Wulfkuhle JD; Gwin WR; Yang X; Gallagher RI; Bacus S; Lyerly HK; Spector NL
    Breast Cancer Res; 2013; 15(5):R85. PubMed ID: 24044505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy.
    García-García C; Ibrahim YH; Serra V; Calvo MT; Guzmán M; Grueso J; Aura C; Pérez J; Jessen K; Liu Y; Rommel C; Tabernero J; Baselga J; Scaltriti M
    Clin Cancer Res; 2012 May; 18(9):2603-12. PubMed ID: 22407832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification.
    Tanizaki J; Okamoto I; Fumita S; Okamoto W; Nishio K; Nakagawa K
    Oncogene; 2011 Sep; 30(39):4097-106. PubMed ID: 21499301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitization of estrogen receptor-positive breast cancer cell lines to 4-hydroxytamoxifen by isothiocyanates present in cruciferous plants.
    Pawlik A; Słomińska-Wojewódzka M; Herman-Antosiewicz A
    Eur J Nutr; 2016 Apr; 55(3):1165-80. PubMed ID: 26014809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
    Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M
    Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab resistance.
    Gayle SS; Arnold SL; O'Regan RM; Nahta R
    Anticancer Agents Med Chem; 2012 Feb; 12(2):151-62. PubMed ID: 22043997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.
    Wang X; Wong J; Sevinsky CJ; Kokabee L; Khan F; Sun Y; Conklin DS
    Mol Cancer Ther; 2016 Sep; 15(9):2198-208. PubMed ID: 27256378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heregulin induces resistance to lapatinib-mediated growth inhibition of HER2-amplified cancer cells.
    Sato Y; Yashiro M; Takakura N
    Cancer Sci; 2013 Dec; 104(12):1618-25. PubMed ID: 24112719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
    Park SH; Ito K; Olcott W; Katsyv I; Halstead-Nussloch G; Irie HY
    Breast Cancer Res; 2015 Jun; 17(1):86. PubMed ID: 26084280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibroblast-tumor cell signaling limits HER2 kinase therapy response via activation of MTOR and antiapoptotic pathways.
    Zervantonakis IK; Poskus MD; Scott AL; Selfors LM; Lin JR; Dillon DA; Pathania S; Sorger PK; Mills GB; Brugge JS
    Proc Natl Acad Sci U S A; 2020 Jul; 117(28):16500-16508. PubMed ID: 32601199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer.
    Korkola JE; Collisson EA; Heiser M; Oates C; Bayani N; Itani S; Esch A; Thompson W; Griffith OL; Wang NJ; Kuo WL; Cooper B; Billig J; Ziyad S; Hung JL; Jakkula L; Feiler H; Lu Y; Mills GB; Spellman PT; Tomlin C; Mukherjee S; Gray JW
    PLoS One; 2015; 10(7):e0133219. PubMed ID: 26181325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repression.
    Nencioni A; Cea M; Garuti A; Passalacqua M; Raffaghello L; Soncini D; Moran E; Zoppoli G; Pistoia V; Patrone F; Ballestrero A
    PLoS One; 2010 Feb; 5(2):e9024. PubMed ID: 20126311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells.
    Fujimoto Y; Morita TY; Ohashi A; Haeno H; Hakozaki Y; Fujii M; Kashima Y; Kobayashi SS; Mukohara T
    Sci Rep; 2020 Dec; 10(1):21762. PubMed ID: 33303839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib.
    Elster N; Cremona M; Morgan C; Toomey S; Carr A; O'Grady A; Hennessy BT; Eustace AJ
    Breast Cancer Res Treat; 2015 Jan; 149(2):373-83. PubMed ID: 25528022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combinatorial effects of lapatinib and rapamycin in triple-negative breast cancer cells.
    Liu T; Yacoub R; Taliaferro-Smith LD; Sun SY; Graham TR; Dolan R; Lobo C; Tighiouart M; Yang L; Adams A; O'Regan RM
    Mol Cancer Ther; 2011 Aug; 10(8):1460-9. PubMed ID: 21690228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.
    Takeda T; Yamamoto H; Kanzaki H; Suzawa K; Yoshioka T; Tomida S; Cui X; Murali R; Namba K; Sato H; Torigoe H; Watanabe M; Shien K; Soh J; Asano H; Tsukuda K; Kitamura Y; Miyoshi S; Sendo T; Toyooka S
    PLoS One; 2017; 12(2):e0171356. PubMed ID: 28158234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.